Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $42.6 million.

  • Anika Therapeutics' Total Liabilities fell 1728.53% to $42.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.6 million, marking a year-over-year decrease of 1728.53%. This contributed to the annual value of $48.8 million for FY2024, which is 1647.51% down from last year.
  • Anika Therapeutics' Total Liabilities amounted to $42.6 million in Q3 2025, which was down 1728.53% from $40.0 million recorded in Q2 2025.
  • Anika Therapeutics' 5-year Total Liabilities high stood at $85.6 million for Q1 2021, and its period low was $40.0 million during Q2 2025.
  • Over the past 5 years, Anika Therapeutics' median Total Liabilities value was $57.7 million (recorded in 2023), while the average stood at $58.0 million.
  • As far as peak fluctuations go, Anika Therapeutics' Total Liabilities plummeted by 5233.04% in 2021, and later soared by 891.73% in 2023.
  • Anika Therapeutics' Total Liabilities (Quarter) stood at $60.4 million in 2021, then rose by 5.15% to $63.6 million in 2022, then decreased by 8.18% to $58.4 million in 2023, then dropped by 16.48% to $48.8 million in 2024, then decreased by 12.55% to $42.6 million in 2025.
  • Its last three reported values are $42.6 million in Q3 2025, $40.0 million for Q2 2025, and $42.2 million during Q1 2025.